Dogwood converts $19.9M debt and interest to Series A-1 preferred equity

Dogwood Therapeutics, Inc.

$19.5M principal plus accrued interest ($19,926,891 total) exchanged for 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock.
Each preferred share convertible into 10,000 common shares, pending stockholder approval and Nasdaq rules.
All existing debt removed from balance sheet; company funded through Q4 2025 interim of Phase 2b CINP trial.
Largest shareholder CK Life Sciences (through Conjoint) facilitated the conversion, signaling confidence in Halneuron program.

item 1.01 item 5.03 item 3.02 item 3.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.